John Gribben of Barts Cancer Institute, London, UK, chairs an insightful discussion with Barbara Eichhorst of the University of Cologne, Cologne, Germany, Susan O�Brien of the University of California, Irvine, CA, and Matthew Davids of Dana-Farber Cancer Institute, Boston, MA, on the latest CLL updates from the recent Virtual ASCO and EHA 2020 Meetings. The speakers discuss frontline therapy for CLL, BTK inhibitors, novel combination therapies and the importance of measurable residual disease (MRD) assessment. Treatment sequencing and novel therapies, in particular CAR T-cell approaches were also discussed.

Natalie Callander, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, Fredrik Schjesvold, MD, PhD, of the Oslo Myeloma Center Oslo University, Oslo, Norway, Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, and Philippe Moreau, MD, of the Nantes University Hospital, Nantes, France, discuss the latest data on the use of MRD in the management and treatment of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021).

Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, Noemi Puig, MD, PhD, of the University Hospital Salamanca, Salamanca, Spain, and Benjamin Derman, MD, of the University of Chicago, Chicago, IL, discuss key research, presented at this year�s Congress of the European Hematology Association (EHA 2021), investigating the role of MRD in the management of multiple myeloma.

Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Anthony Mato, MD, and Meghan Thompson, MD, both from Memorial Sloan Kettering Cancer Center, New York, NY, discuss some of the latest updates in CLL treatment presented at this year�s virtual American Society of Hematology (ASH) meeting.

CLL is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the bone marrow, lymphatic tissue and blood. CLL generally affects the older population and is incurable, however, several novel treatment approaches have developed to improve outcomes of patients with CLL and there is an increasing use of MRD in disease monitoring. In this podcast, Lydia Scarf�, of Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Othman Al-Sawaf of the University Hospital of Cologne, Cologne, Germany, and Tanya Siddiqi, from City of Hope, Duarte, CA discuss key developments in the treatment of CLL presented at this years EHA meeting.

Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what MRD is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community, the way MRD test results will be used in the future, and so much more.

MRD refers to the small number of cancer cells that remain in the body after treatment. In this episode, Gail Roboz, MD, from Weill Cornell Medical College, provides an overview of MRD, including understanding its definition, explains the role advancements in technology have played in detection, and underscores the importance of understanding to what degree this detection can be helpful. Dr. Roboz provides strategies to communicate with patients about the impact of MRD on prognosis, treatment and outcomes and discusses the future of MRD testing in blood cancers.

Featuring an interview with Dr Steven Coutre on the following topics: Front-line treatment of CLL (0:00) Recent data with ibrutinib-based regimens as first-line therapy for CLL (5:31) Results of the Phase III ELEVATE-TN study evaluating the efficacy and safety of acalabrutinib with obinutuzumab compared to acalabrutinib alone or obinutuzumab with chlorambucil for treatment-naive CLL (14:22) Case: A man in his late 70s experiences atrial fibrillation after receiving ibrutinib as first-line treatment for CLL (19:08) Case: A woman in her early 60s develops arthralgias after treatment with ibrutinib for CLL (25:08) Case: A man in his early 70s receiving ibrutinib for CLL experiences easy bruising on his forearms (27:28) Results from the CLL14 trial evaluating the addition of venetoclax versus chlorambucil to obinutuzumab for patients with previously untreated CLL and coexisting medical conditions (32:06) Monitoring and management of tumor lysis syndrome (TLS) in patients receiving venetoclax (37:07) Impact of minimal residual disease (MRD) assessment on outcomes for patients with CLL (41:26) Spectrum of adverse events with Bruton tyrosine kinase (BTK) inhibitors for CLL (46:22) CME information and select publications.

Featuring discussions on the role of minimal residual disease evaluation in the management of multiple myeloma and chronic lymphocytic leukemia with Drs Shaji Kumar and Philip Thompson, moderated by Dr Neil Love.

In this podcast, we�ll look at research demonstrating that the histone acetyltransferase HBO1 is an essential regulator of hematopoietic stem cell function during adult hematopoiesis. Next, we�ll review a large, combined analysis confirming the prognostic value of MRD assessed with next-generation sequencing in 4 randomized trials evaluating daratumumab-based therapies. We�ll conclude with research demonstrating that ferroptosis, a specific type of regulated cell death, is a key mechanism of cardiomyopathy in sickle cell disease.

In this episode, we will review a study that shows that non-invasive imaging of T cell metabolic activity can detect early graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, learn more about how detailed assessment of measurable residual disease in multiple myeloma can better define outcomes and how treatment resistance arises, and finally, examine the mechanism of action and pharmacokinetics of Ciraparantag, a small molecule being developed to rapidly reverse the effects of anticoagulants.

Drs. Rafael Fonseca and Tara Graff�discuss the benefits of MRD testing for patients with Multiple Myeloma and CLL, the importance of training the multidisciplinary care team, and the promise of MRD testing to improve patient outcomes as its adoption continues to grow.

Of all the hematologic malignancies, multiple myeloma has one of the greatest disparities in incidence and prevalence, with incidence in African American patients more than twice that in white patients. These podcasts will teach clinicians culturally sensitive approaches for management of multiple myeloma in African Americans, how to address barriers due to racial disparities, and strategies to implement newly gained knowledge for the best outcomes of African American patients with multiple myeloma.

In this podcast, we chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more.

John Gribben of Barts Cancer Institute, London, UK, chairs an insightful discussion with Barbara Eichhorst of the University of Cologne, Cologne, Germany, Susan O�Brien of the University of California, Irvine, CA, and Matthew Davids of Dana-Farber Cancer Institute, Boston, MA, on the latest CLL updates from the recent Virtual ASCO and EHA 2020 Meetings. The speakers discuss frontline therapy for CLL, BTK inhibitors, novel combination therapies and the importance of measurable residual disease (MRD) assessment. Treatment sequencing and novel therapies, in particular CAR T-cell approaches were also discussed.

Natalie Callander, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, Fredrik Schjesvold, MD, PhD, of the Oslo Myeloma Center Oslo University, Oslo, Norway, Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, and Philippe Moreau, MD, of the Nantes University Hospital, Nantes, France, discuss the latest data on the use of MRD in the management and treatment of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021).

Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, Noemi Puig, MD, PhD, of the University Hospital Salamanca, Salamanca, Spain, and Benjamin Derman, MD, of the University of Chicago, Chicago, IL, discuss key research, presented at this year�s Congress of the European Hematology Association (EHA 2021), investigating the role of MRD in the management of multiple myeloma.

Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Anthony Mato, MD, and Meghan Thompson, MD, both from Memorial Sloan Kettering Cancer Center, New York, NY, discuss some of the latest updates in CLL treatment presented at this year�s virtual American Society of Hematology (ASH) meeting.

CLL is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the bone marrow, lymphatic tissue and blood. CLL generally affects the older population and is incurable, however, several novel treatment approaches have developed to improve outcomes of patients with CLL and there is an increasing use of MRD in disease monitoring. In this podcast, Lydia Scarf�, of Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Othman Al-Sawaf of the University Hospital of Cologne, Cologne, Germany, and Tanya Siddiqi, from City of Hope, Duarte, CA discuss key developments in the treatment of CLL presented at this years EHA meeting.

Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what MRD is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community, the way MRD test results will be used in the future, and so much more.